ArticleInternational journal of clinical oncology2026
Identification and functional validation of lipid droplet-associated prognostic biomarkers in breast cancer via integrative multi-omics and machine learning approaches.
Article in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundLipid droplet (LD)-associated metabolic reprogramming plays a critical role in breast cancer progression and immune modulation, yet robust prognostic biomarkers and their functional mechanisms remain incompletely understood. This study aimed to identify LD-associated biomarkers with prognostic and therapeutic relevance through multi-omics integration and functional validation.
methodsBulk transcriptomic, single-cell RNA sequencing, and spatial transcriptomic data were integrated using machine learning to construct a prognostic model in the TCGA-BRCA cohort, validated in merged GEO datasets (GSE24450 and GSE42568). Functional enrichment, immune infiltration analyses, and in vitro/in vivo experiments-including 3T3-L1 adipogenesis, co-culture, orthotopic tumor models, and clinical adipose tissue validation were performed to characterize candidate genes.
resultsThe StepCox[both]+plsRcox algorithm generated an optimal prognostic model that independently stratified patients across molecular subtypes, outperforming ER/PR/HER2 status. High-risk patients exhibited reduced immune infiltration and T-cell dysfunction. SQLE and SOCS3 emerged as key LD-associated genes with opposing expression patterns: SQLE enriched in tumor-associated adipocytes and SOCS3 in immune cells. Functional assays confirmed SQLE promoted while SOCS3 inhibited adipogenesis. Modulating these genes in adipocytes suppressed tumor growth and EMT and polarized macrophages toward an M1-dominant phenotype.
conclusionsSQLE and SOCS3 serve as functionally significant LD-associated prognostic biomarkers and represent promising therapeutic targets in breast cancer, revealing novel mechanisms in tumor-adipocyte crosstalk.
Indexed as
Identifiers
42484744What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.